T1	Intervention 54 65	Ocriplasmin
T2	Intervention 109 158	Microplasmin for Intravitreous Injection-Traction
T3	Intervention 241 269	vitreomacular adhesion (VMA)
T4	Intervention 449 473	intravitreal ocriplasmin
T5	Intervention 581 593	(NEI VFQ-25)
T6	Intervention 1298 1312	of ocriplasmin
T7	Intervention 1323 1360	or placebo-injected vehicle (placebo)
T8	Intervention 1362 1376	The NEI VFQ-25
T9	Intervention 1419 1440	following ocriplasmin
T10	Intervention 1521 1541	follow-up NEI VFQ-25
T11	Intervention 1707 1727	received ocriplasmin
T12	Intervention 1736 1752	received placebo
T13	Intervention 1841 1855	the NEI VFQ-25
T14	Intervention 1877 1888	the placebo
T15	Intervention 2042 2064	for the ocriplasmin vs
T16	Intervention 2286 2303	higher proportion
T17	Intervention 2466 2492	respectively; P = .03)
T18	Intervention 2570 2582	their visual
T19	Intervention 2703 2726	various subscale scores
T20	Intervention 2804 2811	day 28.
T21	Intervention 2812 2823	CONCLUSIONS
